ADME Toxicology - The Online Scientific Community

Press Releases & Product Announcements

Please send all press releases and product announcements to pr@technologynetworks.com Wherever possible, press releases should be emailed as a Microsoft Word attachment or embedded in the email itself. Images should be sent as separate attachments. Where possible please insert the name(s) of the community(ies) that you wish the press release to be published on into the subject line of the email.

For a full list of all Technology Networks’ communities please click here

Submitting Application Notes

By submitting your application notes to us for online publication you are agreeing to the Terms and Conditions for the application notes section of Technology Networks' communities and, confirming that you have the required copyright to submit these application notes.

Application notes should be submitted to apps@technologynetworks.com preferably as a PDF, if not as a Microsoft Publisher or PowerPoint file. A 40 - 70 word summary must be sent with each application note submitted.

The name(s) of the website(s) that you wish the application note to be published on should be entered into the subject line of the email. For a full list of all Technology Networks’ communities please click here

Before submitting an application note for online publication please read the terms and conditions below.

Submitting a Poster

Posters submitted by academics and from not-for-profit organizations will be published free of charge. For commercial companies there will be an administration charge of $200 for each poster published. Please contact Kelly Giles for more information.

By submitting your poster to us for online publication you are agreeing to the Terms and Conditions for the Posters section of Technology Networks' communities and confirming that you have the required copyright to submit these posters.

Posters should be submitted using the online submission form which is located within the posters section of each website, (click “submit poster” link). The poster needs to be submitted as a PDF or Microsoft PowerPoint file. A 40 – 70 word summary must be submitted along with the poster.

If you have any problems with you submission, please contact posters@technologynetworks.com, stating the name of the website you wish to publish your poster on in the subject line.

Before submitting a poster for online publication please read the terms and conditions below.

TERMS AND CONDITIONS

1. Services / Consideration.
Technology Networks Ltd. ('TechNet') shall develop an electronic version of the printed Application Note or Poster that has been created from the files provided by you (the 'Author'). In consideration of TechNet's development, archiving and retrieval of the Author's Application note, Author shall: (a) grant the license stated in Section 3.

2. Copyright Ownership.
As between TechNet and Author, Author shall be the owner of all copyrights in and to the content contained in the Print Application Note or poster and the online Application Note or Poster.

3. Copyright License.
In order for TechNet to electronically archive, display and distribute the Application Note or Poster, Author hereby grants to TechNet an irrevocable, perpetual license to maintain, store, cache, copy and distribute (in any current or future media) the Application Note or Poster (the 'License Grant'). The License Grant includes TechNet's right to include the Application Note or Poster in its current and future database or databases as well as to distribute the Application Note or Poster electronically to third parties through any one or more websites operated by or on behalf of TechNet.

4.Representations and Warranties.
Author hereby represents and warrants to TechNet that: (i) Author is the owner or authorized licensee of all right, title and interest (including all copyrights and other intellectual property rights) in and to all content that appears on the Application Note or Poster; (ii) all content that appears in the Application Note or Poster is the Author's original work and contains no libelous or unlawful statements, does not infringe on the rights or privacy of others or contain material or instructions that might cause harm or injury, (iii) Author's execution and performance of this Agreement does not and shall not constitute a breach of, or otherwise violate, any written or verbal understanding or agreement between Author and any third party; and (iv) TechNet's use of the files provided by the Author to create the Application Note or Poster, as well as TechNet's exercise of its rights pursuant to the License Grant, shall not infringe or violate the copyrights, or other intellectual property rights, of any third party.

5.Miscellaneous.
(a) This Agreement shall be construed and enforced in accordance with the laws of the United Kingdom. Each party hereby consents to the exclusive jurisdiction and venue of any court located in the United Kingdom with respect to any claim or controversy arising out of or related to this Agreement.

(b) This Agreement: (i) shall benefit and bind each party and their successors and assigns; (ii) contains the entire understanding and agreement of the parties; and it incorporates or supersedes all other written or verbal agreements and understandings with respect to the subject matter; and (iii) may be amended or modified only in writing signed by both parties and referring specifically to the Agreement.

Pharmacokinetics, Metabolism and Toxicity of Carbon Nanotubes for Biomedical Purposes
This study reviews the updated data of CNTs from the biomedical view with focus on the pharmacokinetics, metabolism and toxicity of CNTs in vivo.

Fall in Deaths Following Withdrawal of Pain Killer
Reduction in deaths after withdrawn of pain-relief drug co-proxamol in UK.

Urinary Excretion of Platinum, Arsenic and Selenium of Cancer Patients Treated with Platinum-Based Drugs
Arsenic exposure increases the risk of non-cancerous and cancerous diseases. This study characterised the short-term urinary excretion amounts of arsenic, selenium and platinum in 24-h urine samples from patients with lung cancer and those with other types of cancer.

Inroads to Predict in Vivo Toxicology—An Introduction to the eTOX Project
The main barrier for a new drug to enter into clinical development is the preclinical evaluation of toxicity. This project aims to be a database consisting of preclinical toxicity data for drug compounds or candidates extracted from, previously unpublished, legacy reports.

Real-Time Visualization and Quantitation of Vascular Permeability In Vivo: Implications for Drug Delivery
This paper presents an integrated method to visualize and quantify the real-time dynamics of dextrans in a shell-less chick chorioallantoic (CAM) model.

Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Nanomolar Potency
This article looks at prediction of cancer drug efficacy in its ultimate user, the human patient and reviews current knowledge followed by illustrative examples that, in the absence of definitive data, provide an empirical perspective.

Direct Drug Metabolism Monitoring in a Live Single Hepatic Cell by Video Mass Spectrometry
This study of live single-cell level drug metabolism analysis opens the possibility of speedy, low-cost and site-specific monitoring of drug metabolism and a useful tool for single-cell tailored medicine using biopsied cells.

Evaluation of Drug Administration Errors in a Teaching Hospital
The evaluation and improvement of drug administration process are key elements in patient safety. Researchers directly observed the frequency, type, potential clinical significance and determinants of drug administration errors detected in adult in-patients, with the aim to overcome methodological limitations.

Global Patterns of Genetic Diversity and Signals of Natural Selection for Human ADME Genes
This study is the first to systematically investigate worldwide population differentiation and potential signals of natural selection in a comprehensive list of ADME genes.